Profile data is unavailable for this security.
About the company
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-40.16m
- Incorporated2018
- Employees42.00
- LocationVincerx Pharma Inc260 Sheridan Avenue, Suite 400PALO ALTO 94306United StatesUSA
- Phone+1 (650) 800-6676
- Fax+1 (302) 655-5049
- Websitehttps://vincerx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacyte Biotech Inc | 0.00 | -14.82m | 18.60m | 2.00 | -- | 0.5975 | -- | -- | -1.64 | -1.64 | 0.00 | 5.74 | 0.00 | -- | -- | 0.00 | -1.53 | -13.35 | -1.62 | -13.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1.81 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.28m | 18.66m | 0.00 | -- | 69.30 | -- | -- | -0.0799 | -0.0799 | 0.00 | 0.0144 | 0.00 | -- | -- | -- | -382.14 | -- | -688.47 | -- | -- | -- | -- | -- | -- | -106.00 | 0.1246 | -- | -- | -- | 61.76 | -- | -- | -- |
| Biomx Inc | 0.00 | -26.17m | 18.77m | 58.00 | -- | 5.07 | -- | -- | -0.5433 | -0.5433 | 0.00 | 0.067 | 0.00 | -- | -- | 0.00 | -74.18 | -- | -101.74 | -- | -- | -- | -- | -- | -- | -21.95 | 0.7841 | -- | -- | -- | 7.59 | -- | -- | -- |
| Alaunos Therapeutics Inc | 5.00k | -35.14m | 18.89m | 1.00 | -- | 3.00 | -- | 3,778.95 | -2.20 | -2.20 | 0.0003 | 0.3939 | 0.0001 | -- | 2.00 | 5,000.00 | -96.01 | -74.83 | -149.28 | -89.57 | -- | -- | -702,800.00 | -10,508.06 | -- | -14.83 | 0.00 | -- | -99.83 | -49.08 | 6.86 | -- | -15.56 | -- |
| China Health Industries Holdings, Inc. | 117.28k | -1.51m | 19.16m | 32.00 | -- | -- | -- | 163.40 | -0.023 | -0.023 | 0.0018 | -0.0349 | 0.0044 | 0.5692 | 25.25 | 3,665.00 | -5.72 | 3.04 | -7.60 | 3.66 | -2.37 | 69.55 | -1,287.13 | 28.61 | 0.0377 | -- | 1.68 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
| Flora Growth Corp | 76.07m | -47.36m | 19.87m | 97.00 | -- | 2.16 | -- | 0.2612 | -6.62 | -7.97 | 10.04 | 0.7167 | 1.45 | 6.76 | 31.13 | 784,237.10 | -89.22 | -- | -130.91 | -- | 23.32 | -- | -61.35 | -- | 0.7897 | -- | 0.2317 | -- | 127.75 | -- | -1.87 | -- | -- | -- |
| Vincerx Pharma Inc | 0.00 | -40.16m | 19.91m | 42.00 | -- | 1.77 | -- | -- | -1.89 | -1.89 | 0.00 | 0.5242 | 0.00 | -- | -- | 0.00 | -103.63 | -- | -128.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.24 | -- | -- | -- |
| Indaptus Therapeutics Inc | 0.00 | -15.42m | 20.07m | 7.00 | -- | 1.63 | -- | -- | -1.84 | -1.84 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -71.76 | -66.55 | -83.87 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
| Allied Corp | 21.51k | -10.20m | 20.11m | -- | -- | -- | -- | 934.69 | -0.1046 | -0.1046 | 0.0002 | -0.0712 | 0.0054 | 2.10 | 0.1673 | -- | -258.20 | -- | -- | -- | -6,919.57 | -- | -47,432.82 | -- | 0.0234 | -36.24 | -- | -- | -56.46 | -- | 31.30 | -- | -- | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 20.22m | 4.00 | -- | -- | -- | 26,959.75 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| OncoCyte Corp | 1.50m | -25.80m | 20.35m | 43.00 | -- | 0.9929 | -- | 13.54 | -3.08 | -3.47 | 0.1869 | 3.10 | 0.0172 | -- | 1.20 | 34,953.49 | -28.41 | -35.11 | -31.93 | -39.71 | 27.48 | -- | -1,653.69 | -2,373.36 | -- | -146.07 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
| RenovoRx Inc | 0.00 | -10.23m | 20.46m | 8.00 | -- | -- | -- | -- | -1.01 | -1.01 | 0.00 | -0.2805 | 0.00 | -- | -- | 0.00 | -234.38 | -- | -317.07 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -3.47 | -- | -- | -- |
| Biora Therapeutics Inc | 4.00k | -124.33m | 20.64m | 58.00 | -- | -- | -- | 5,159.45 | -8.57 | -8.56 | 0.0003 | -4.28 | 0.00009 | -- | 0.0048 | 68.97 | -293.45 | -122.84 | -- | -369.01 | -- | -- | -3,108,350.00 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| Context Therapeutics Inc | 0.00 | -23.96m | 20.76m | 5.00 | -- | 1.75 | -- | -- | -1.50 | -1.50 | 0.00 | 0.7435 | 0.00 | -- | -- | 0.00 | -88.71 | -- | -102.79 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
Data as of Apr 25 2024. Currency figures normalised to Vincerx Pharma Inc's reporting currency: US Dollar USD
34.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sage Rhino Capital LLCas of 31 Dec 2023 | 1.70m | 7.97% |
| Long Focus Capital Management LLCas of 31 Dec 2023 | 1.10m | 5.14% |
| BofA Securities, Inc.as of 31 Dec 2023 | 1.08m | 5.07% |
| Rock Springs Capital Management LPas of 31 Dec 2023 | 891.72k | 4.17% |
| Goldman Sachs & Co. LLC (Private Banking)as of 28 Mar 2024 | 631.49k | 2.95% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 507.46k | 2.37% |
| Kingdon Capital Management LLCas of 31 Dec 2023 | 385.00k | 1.80% |
| Rubric Capital Management LPas of 31 Dec 2023 | 354.38k | 1.66% |
| Point72 Asset Management LPas of 31 Dec 2023 | 344.83k | 1.61% |
| ExodusPoint Capital Management LPas of 31 Dec 2023 | 324.12k | 1.52% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
